The infectious disease diagnostics market size was valued at USD 46.81 billion in 2025 and estimated to grow from USD 48.38 billion in 2026 to reach USD 57.05 billion by 2031, at a CAGR of 3.35% during the forecast period (2026-2031). This report is Segmented by Application (Hepatitis, HIV, and More), by Product & Service (Assays, Kits, & Reagents, and More), by Technology (PCR & QPCR, and More), End User (Hospital & Clinical Laboratories, and More), Test Setting (Laboratory-Based Testing, and More), Sample Type(Urine, Stool and More) and Geography. The Market Forecasts are Provided in Terms of Value (USD).
Growth relies on rapid antimicrobial susceptibility tools for hospital-acquired infections and FDA OTC clearances for STI home kits. Laboratories value platforms that update quickly when the WHO adds bacteria to its resistance list; such flexibility strengthens vendor stickiness inside the infectious disease diagnostics market.
Assays, kits, and reagents contributed 52.90% of infectious disease diagnostics market size in 2025 because consumables drive recurring revenue. Software and informatics, though smaller, will post the quickest 5.48% CAGR as labs digitize workflows. Instruments now compete on automation depth, sample-to-answer speed, and AI tie-ins rather than raw throughput alone.
Contract-testing services grow when hospitals outsource complex sequencing or drug-resistance panels. Cloud-based analytics link raw data to actionable reports, enhancing value per test. Vendors bundling reagents with informatics maintain share even as hardware margins tighten across the infectious disease diagnostics market.
Asia-Pacific is projected to grow at a 5.20% CAGR to 2031 owing to infrastructure investment and rising infectious-disease burdens. Government programs in China, India, and Japan subsidize rapid dengue, mpox, and antimicrobial-resistance panels, which shortens adoption cycles. Digital health pilots link remote kits to teleconsults, increasing reach in rural regions.
Europe maintains steady demand and leads syndromic multiplex adoption. Fragmented reimbursement and data-privacy legislation slow cross-border digital-health scaling, yet antimicrobial-stewardship initiatives keep pressure on hospitals to deploy rapid diagnostics. Middle East and Africa markets remain smaller but are receiving donor-funded upgrades that create footholds for suppliers seeking geographic diversification within the infectious disease diagnostics market.
Global Infectious Disease Diagnostics Market Trends and Insights
Escalating Prevalence and Resurgence of Infectious Diseases
Vector-borne illnesses are climbing, with dengue cases running 15% above the five-year average in early 2025.Climate change is widening mosquito habitats, so providers now test for pathogens once restricted to the tropics. The World Health Organization classified mpox as a grade 3 emergency in August 2024, prompting a 160% jump in test demand over the prior year. Antimicrobial resistance adds pressure: the WHO’s 2024 priority list highlights 15 resistant bacterial families that need rapid diagnostics. As new threats surface, laboratories must refresh menus frequently, creating recurring revenue for firms across the infectious disease diagnostics market.Growing Demand for Point-of-Care and At-Home Testing
Regulators are green-lighting consumer tests at pace. In August 2024 the FDA cleared the first OTC syphilis assay, ushering retail diagnostics into mainstream practice. Syphilis incidence rose 80% from 2018 to 2022, so community pharmacies and e-commerce portals now stock rapid kits. Cepheid’s finger-stick hepatitis C test adds same-visit viral confirmation, closing care gaps in primary clinics. Payers value earlier therapy starts that reduce downstream costs, so reimbursement processes are catching up, even as coding complexity persists.Fragmented and Inadequate Reimbursement Frameworks
Payers insist on stringent coding before honoring claims, and the added paperwork stretches cash cycles for smaller labs. Government fee schedules, especially in low- and middle-income countries, rarely cover the full cost of advanced molecular platforms, limiting uptake. Laboratories in such settings rely on donor programs, slowing commercial momentum despite clear clinical need. Harmonized payment models would unlock wider adoption across the infectious disease diagnostics market.Other drivers and restraints analyzed in the detailed report include:
- Continuous Innovation in PCR/NGS Platforms and Chemistries
- AI-Driven Laboratory Workflows for Testing
- Budget Squeeze After COVID-19 Testing Wind-Down
Segment Analysis
Respiratory panels held 19.85% of infectious disease diagnostics market share in 2025, yet vector-borne and emerging pathogens are set to climb at a 5.52% CAGR to 2031. A record 13 million dengue cases in 2024-2025 forced hospitals to expand test menus. Mpox, hepatitis, HIV self-tests, and AI-assisted tuberculosis assays broaden the clinical mix. The infectious disease diagnostics market size attached to vector-borne testing will keep rising as global mobility and climate change alter transmission zones.Growth relies on rapid antimicrobial susceptibility tools for hospital-acquired infections and FDA OTC clearances for STI home kits. Laboratories value platforms that update quickly when the WHO adds bacteria to its resistance list; such flexibility strengthens vendor stickiness inside the infectious disease diagnostics market.
Assays, kits, and reagents contributed 52.90% of infectious disease diagnostics market size in 2025 because consumables drive recurring revenue. Software and informatics, though smaller, will post the quickest 5.48% CAGR as labs digitize workflows. Instruments now compete on automation depth, sample-to-answer speed, and AI tie-ins rather than raw throughput alone.
Contract-testing services grow when hospitals outsource complex sequencing or drug-resistance panels. Cloud-based analytics link raw data to actionable reports, enhancing value per test. Vendors bundling reagents with informatics maintain share even as hardware margins tighten across the infectious disease diagnostics market.
Complete Report Scope:
- By Application
- Hepatitis (A, B, C, D, E)
- HIV / AIDS
- CT/NG & Other STIs
- Tuberculosis
- Respiratory (Influenza, RSV, COVID-19, Others)
- Vector-borne & Emerging Pathogens (Dengue, Zika, Mpox)
- Hospital-Acquired Infections (MRSA, C. diff, etc.)
- Others (Malaria, Lyme, Toxoplasmosis)
- By Product & Service
- Assays, Kits & Reagents
- Instruments & Analyzers
- Software & Informatics
- Services & Contract Testing
- By Technology
- PCR & qPCR
- Isothermal NAAT (LAMP, INAAT, TMA)
- Immunodiagnostics (ELISA, CLIA, LFIA)
- DNA/RNA Sequencing & NGS
- Microarray & Multiplex Panels
- CRISPR-based Diagnostics
- Metagenomic & Shotgun Sequencing
- By End User
- Hospital & Clinical Laboratories
- Reference / Central Laboratories
- Point-of-Care / Decentralised Settings
- Home-care & OTC Consumers
- Academic & Research Institutes
- By Test Setting
- Laboratory-based Testing
- Point-of-Care Testing
- Over-the-Counter / At-Home Testing
- By Sample Type
- Blood / Plasma / Serum
- Swab (NP/OP, Saliva)
- Urine
- Stool
- Other Fluids (CSF, Sputum, etc.)
- By Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East and Africa
- GCC
- South Africa
- Rest of Middle East and Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Geography Analysis
North America generated 44.85% of global revenue in 2025, supported by established reimbursement rules, fast FDA clearances, and high routine screening volume. However, the region is now confronting budget compression as COVID-19 testing revenues fade, prompting labs to broaden menus and accelerate automation.Asia-Pacific is projected to grow at a 5.20% CAGR to 2031 owing to infrastructure investment and rising infectious-disease burdens. Government programs in China, India, and Japan subsidize rapid dengue, mpox, and antimicrobial-resistance panels, which shortens adoption cycles. Digital health pilots link remote kits to teleconsults, increasing reach in rural regions.
Europe maintains steady demand and leads syndromic multiplex adoption. Fragmented reimbursement and data-privacy legislation slow cross-border digital-health scaling, yet antimicrobial-stewardship initiatives keep pressure on hospitals to deploy rapid diagnostics. Middle East and Africa markets remain smaller but are receiving donor-funded upgrades that create footholds for suppliers seeking geographic diversification within the infectious disease diagnostics market.
List of Companies Covered in this Report:
- Abbott Laboratories
- Roche
- Danaher (Cepheid & Beckman Coulter)
- bioMérieux
- Thermo Fisher Scientific
- Beckton Dickinson
- Siemens Healthineers
- Bio-Rad Laboratories
- DiaSorin (Luminex)
- Quidel-Ortho
- Hologic
- QIAGEN
- Sysmex
- Seegene
- Quest Diagnostics
- Lucira Health
- GenMark Diagnostics
- Oxford Nanopore Technologies
- T2 Biosystems
- Sherlock Biosciences
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
Table of Contents
1 Introduction
4 Market Landscape
5 Market Size and Growth Forecasts (Value-USD)
6 Competitive Landscape
7 Market Opportunities and Future Outlook
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- F. Hoffmann-La Roche AG
- Danaher (Cepheid & Beckman Coulter)
- bioMérieux SA
- Thermo Fisher Scientific
- Becton, Dickinson and Company
- Siemens Healthineers
- Bio-Rad Laboratories
- DiaSorin (Luminex)
- Quidel-Ortho
- Hologic Inc.
- Qiagen N.V.
- Sysmex Corporation
- Seegene Inc.
- Quest Diagnostics
- Lucira Health
- GenMark Diagnostics
- Oxford Nanopore Technologies
- T2 Biosystems
- Sherlock Biosciences
